Ambrisentan Clinical Trials
4 recruitingDrug
Not Applicable2Phase 21Phase 31
Showing 1–4 of 4 trials
Recruiting
Phase 3
COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities
ComorbiditiesCardiovascular Disease (CVD)Pulmonary Arterial Hypertension PAH
Assistance Publique - Hôpitaux de Paris186 enrolled1 locationNCT07245680
Recruiting
Not Applicable
Comparison of Sequential to Initial Combination Therapy in PAH
Pulmonary Arterial Hypertension PAH
Second Affiliated Hospital, School of Medicine, Zhejiang University376 enrolled1 locationNCT06968962
Recruiting
Phase 2
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Noorik Biopharmaceuticals AG54 enrolled6 locationsNCT06256432
Recruiting
Not Applicable
Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Nanjing First Hospital, Nanjing Medical University420 enrolled1 locationNCT04972656